Novo Nordisk had a record-breaking 2021 profit, but has reined in expectations for 2022
In 2021, Novo Nordisk has lifted both its revenue and profits to new heights, driven by great progress of its diabetes flagship semaglutide in both tablet and injection form. There are challenges ahead, however, the company warns, as it predicts less progress in 2022.
By Mikkel Aabenhus Hemmingsen, translated by Daniel Pedersen
2021 was a historically good year for Novo Nordisk, which has never achieved such high revenue and profit results before, the company’s full-year report, released on Wednesday morning, states.